粒子線治療の世界市場予測(~2023年)

【英語タイトル】Particle Therapy Market by Type (Heavy Ion, Proton Therapy), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate, Breast), Application (Treatment, Research) - Forecast to 2023

MarketsandMarketsが出版した調査資料(MD-6747)・商品コード:MD-6747
・発行会社(調査会社):MarketsandMarkets
・発行日:2018年11月16日
・ページ数:139
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥627,150見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥738,150見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥904,650見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
粒子線治療の世界市場は、2018年の8億6500万米ドルから2023年には13億4900万米ドルに達し、9.3%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、粒子線治療が光子療法よりも優れていること、世界中でがんの罹患率が拡大していること、臨床試験において粒子線治療の採用が増加していること、世界中で粒子線治療センターが増加していることなどが考えれられます。当調査レポートでは、粒子線治療の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、タイプ(重粒子イオン、陽子線治療)分析、製品(サイクロトロン、シンクロトロン、シンクロサイクロトロン)分析、サービス分析、システム(シングルルーム、マルチルーム)分析、粒子線治療の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

“The particle therapy market is projected to grow at a CAGR of 9.3% during the forecast period”The global particle therapy market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%. The growth of this market is largely driven by factors such as the various advantages offered by particle therapy over photon therapy, growing global prevalence of cancer, increasing adoption of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide.

“The cyclotrons segment is expected to account for the largest market share during the forecast period”
Based on type, the particle therapy products market is segmented into cyclotrons, synchrotrons, and synchrocyclotrons. The cyclotrons segment is expected to account for the largest share of this market in 2018. The development of technologically advanced systems, advantages offered by cyclotrons over other accelerators, and the growing adoption of cyclotrons among users are the major factors driving the growth of this market segment. Furthermore, the leading player in the particle therapy market with the strongest global footprint—IBA—majorly manufactures cyclotrons. This has greatly boosted the adoption of these products.

“The research applications segment is estimated to grow at the highest rate during the forecast period”
On the basis of application, the particle therapy market has been segmented into treatment and research applications. The research applications segment is estimated to grow at the highest rate during the forecast period due to factors such as the growing awareness about the research applications of particle therapy systems, development of cost-effective and technologically advanced diagnostic and therapeutic particle therapy systems, and the increasing industry-academia collaborations in the field of research.

“North America to account for the second-largest share of the global market in 2018”
The particle therapy market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. North America is expected to account for the second-largest share of the global particle therapy market in 2018. Technological advancements in the field of particle therapy, the rising incidence of cancer, easy accessibility to treatments, and the high adoption of advanced diagnostic technologies (owing to the significant per capita annual healthcare expenditure by the US and Canadian governments) are some of the key factors supporting the growth of the North American market. Furthermore, favorable government initiatives that are creating awareness and promoting the adoption of proton therapy among key end users are some of the other major factors driving the growth of the particle therapy market in North America.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1–25%, Tier 2–30%, and Tier 3–45%
• By Designation: C-level–26%, Director-level–30%, and Others–44%
• By Region: North America–35%, Europe–26%, APAC–23%, and RoW–16%

The major players in the market include Ion Beam Applications SA (Belgium), Varian Medical Systems, Inc. (US), Hitachi, Ltd. (Japan), Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), ProTom International, Inc. (US), Advanced Oncotherapy Plc. (UK), and Danfysik A/S (Denmark).

Research Coverage
This report studies the particle therapy market based on type, product & service, system, cancer type, application, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions (and the respective countries in these regions).

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the particle therapy market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 18
1.5 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 21
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY DATA 23
2.1.2.1 Key data from primary sources 23
2.1.2.2 Breakdown of primaries 24
2.2 MARKET SIZE ESTIMATION 24
2.2.1 PRODUCT-BASED MARKET ESTIMATION 24
2.2.2 VOLUME-BASED MARKET ESTIMATION 26
2.2.3 PRIMARY RESEARCH VALIDATION 28
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 29
2.4 RESEARCH LIMITATIONS AND ASSUMPTIONS 30
2.4.1 LIMITATIONS 30
2.4.2 ASSUMPTIONS 30
3 EXECUTIVE SUMMARY 31
4 PREMIUM INSIGHTS 36
4.1 PARTICLE THERAPY: MARKET OVERVIEW 36
4.2 REGIONAL ANALYSIS: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE 37
4.3 PARTICLE THERAPY MARKET SIZE, BY TYPE 37
4.4 PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE 38
4.5 REGIONAL ANALYSIS: PARTICLE THERAPY MARKET, BY APPLICATION 39
4.6 PARTICLE THERAPY MARKET, BY REGION 40

5 MARKET OVERVIEW 41
5.1 INTRODUCTION 41
5.2 MARKET DYNAMICS 41
5.2.1 DRIVERS 42
5.2.1.1 Advantages offered by particle therapy over photon therapy 42
5.2.1.2 Growing global prevalence of cancer 42
5.2.1.3 Growing adoption of particle therapy in clinical trials 43
5.2.1.4 Increasing number of particle therapy centers worldwide 44
5.2.2 RESTRAINTS 44
5.2.2.1 Infrastructural challenges in healthcare facilities 44
5.2.2.2 Affordability and accessibility of treatments 45
5.2.2.3 Unfavorable reimbursement policies and limited insurance coverage for particle therapy 45
5.2.3 OPPORTUNITIES 46
5.2.3.1 Emerging markets 46
5.2.4 INDUSTRY TRENDS 47
5.2.4.1 GROWING ADOPTION OF PENCIL-BEAM SCANNING 47
6 PARTICLE THERAPY MARKET, BY TYPE 48
6.1 INTRODUCTION 49
6.2 PROTON THERAPY 50
6.2.1 PROTON THERAPY IS INCREASINGLY BEING ADOPTED AS A PRIMARY TREATMENT MODE FOR VARIOUS CANCER TYPES 50
6.3 HEAVY ION THERAPY 51
6.3.1 THE USE OF HEAVY ION THERAPY IS STILL IN THE EXPERIMENTAL PHASE ACROSS MANY REGIONS 51
7 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE 52
7.1 INTRODUCTION 53
7.2 PRODUCTS 54
7.2.1 CYCLOTRONS 56
7.2.1.1 Leading players in the particle therapy market mainly manufacture cyclotrons 56
7.2.2 SYNCHROTRONS 57
7.2.2.1 Increasing investments into the development of synchrotron facilities are contributing to market growth 57
7.2.3 SYNCHROCYCLOTRONS 58
7.2.3.1 The high space requirements of synchrocyclotrons are limiting their widespread adoption 58
7.3 SERVICES 59

8 PARTICLE THERAPY MARKET, BY SYSTEM 60
8.1 INTRODUCTION 61
8.2 MULTI-ROOM SYSTEMS 62
8.2.1 LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES OF MULTI-ROOM SYSTEMS ARE INCREASING INTEREST AMONG END USERS 62
8.3 SINGLE-ROOM SYSTEMS 63
8.3.1 COMPACT STRUCTURE AND REDUCED CAPITAL COSTS ARE LEADING TO HIGH GROWTH OF SINGLE-ROOM SYSTEMS 63
9 PARTICLE THERAPY MARKET, BY CANCER TYPE 64
9.1 INTRODUCTION 65
9.1.1 PEDIATRIC CANCER 66
9.1.1.1 BETTER CONTROL OF RADIATION WITH PARTICLE THERAPY MAKES IT THE MOST SUITABLE TREATMENT MODE FOR PEDIATRIC CANCER 66
9.1.2 PROSTATE CANCER 66
9.1.2.1 PARTICLE THERAPY OFFERS A MINIMALLY INVASIVE ALTERNATIVE WITH INCREASED ACCURACY FOR PROSTATE CANCER TREATMENT 66
9.1.3 LUNG CANCER 67
9.1.3.1 RISING NUMBER OF CLINICAL TRIALS TO OPTIMIZE THE USE OF PARTICLE THERAPY FOR LUNG CANCER IS DRIVING THE GROWTH OF THE MARKET 67
9.1.4 BREAST CANCER 67
9.1.4.1 LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-EFFECTS IS INCREASING THE ADOPTION OF PARTICLE THERAPY FOR BREAST CANCER 67
9.1.5 HEAD AND NECK CANCER 67
9.1.5.1 THE USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY SUPPORTS MARKET GROWTH FOR THIS SEGMENT 67
9.1.6 OTHER CANCERS 68
10 PARTICLE THERAPY MARKET, BY APPLICATION 69
10.1 INTRODUCTION 70
10.2 TREATMENT APPLICATIONS 71
10.2.1 INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTRES IS PROMOTING THE ADOPTION OF PARTICLE THERAPY FOR CANCER TREATMENT 71
10.3 RESEARCH APPLICATIONS 72
10.3.1 INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS IS PROVIDING GROWTH OPPORTUNITIES IN RESEARCH APPLICATIONS 72

11 PARTICLE THERAPY MARKET, BY REGION 74
11.1 INTRODUCTION 75
11.2 NORTH AMERICA 77
11.2.1 US 80
11.2.1.1 Growing number of particle therapy centers in the US to drive market growth 80
11.2.2 CANADA 82
11.2.2.1 Canadian government undertaking initiatives to include particle therapy as a treatment method 82
11.3 EUROPE 83
11.3.1 FRANCE 87
11.3.1.1 Increasing healthcare expenditure in France is supporting the adoption of particle therapy products 87
11.3.2 GERMANY 88
11.3.2.1 Increasing research in the field of proton & heavy ion therapy to drive the growth of the particle therapy market in Germany 88
11.3.3 UK 90
11.3.3.1 Cyclotrons segment dominated the particle therapy market in the UK 90
11.3.4 REST OF EUROPE 91
11.4 ASIA PACIFIC 93
11.4.1 JAPAN 97
11.4.1.1 Japan is the largest user of heavy ion therapy for the treatment of various types of cancers 97
11.4.2 CHINA 99
11.4.2.1 Growing interest of major market players to increase their presence in China will drive the growth of the particle therapy market in the country 99
11.4.3 INDIA 101
11.4.3.1 Leading product manufacturers are entering the Indian particle therapy market owing to the high growth opportunities in the country 101
11.4.4 REST OF ASIA PACIFIC 102
11.5 REST OF THE WORLD 104
11.5.1 INADEQUATE HEALTHCARE INFRASTRUCTURE IS RESTRAINING THE WIDESPREAD ADOPTION OF PARTICLE THERAPY IN THE REGION 104
12 COMPETITIVE LANDSCAPE 108
12.1 INTRODUCTION 108
12.2 MARKET SHARE ANALYSIS 109
12.3 COMPETITIVE SCENARIO 110
12.3.1 PRODUCT LAUNCHES AND APPROVALS 110
12.3.2 ACQUISITIONS 110
12.3.3 EXPANSIONS 111
12.3.4 AGREEMENTS AND COLLABORATIONS 111

13 COMPANY PROFILES: PARTICLE THERAPY MARKET 112
(Business Overview, Products Offered, Recent Developments, MnM View)*
13.1 VARIAN MEDICAL SYSTEMS, INC. 112
13.2 ION BEAM APPLICATIONS SA (IBA) 115
13.3 MEVION MEDICAL SYSTEMS, INC. 118
13.4 PROVISION HEALTHCARE, LLC 120
13.5 SUMITOMO HEAVY INDUSTRIES, LTD. 122
13.6 HITACHI, LTD. 124
13.7 OPTIVUS PROTON THERAPY, INC. 126
13.8 PROTOM INTERNATIONAL, INC. 127
13.9 ADVANCED ONCOTHERAPY PLC. 128
13.10 DANFYSIK A/S 130
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
14 APPENDIX 131
14.1 DISCUSSION GUIDE 131
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 135
14.3 AVAILABLE CUSTOMIZATIONS 137
14.4 RELATED REPORTS 137
14.5 AUTHOR DETAILS 138

LIST OF TABLES

TABLE 1 PARTICLE THERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 49
TABLE 2 PROTON THERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 50
TABLE 3 HEAVY ION THERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 51
TABLE 4 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 53
TABLE 5 PARTICLE THERAPY PRODUCT & SERVICE MARKET, BY REGION,
2016–2023 (USD MILLION) 53
TABLE 6 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 55
TABLE 7 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2023 (UNITS) 55
TABLE 8 PARTICLE THERAPY PRODUCTS MARKET, BY REGION, 2016–2023 (USD MILLION) 55
TABLE 9 CYCLOTRONS MARKET, BY REGION, 2016–2023 (USD MILLION) 56
TABLE 10 CYCLOTRONS MARKET, BY REGION, 2016–2023 (UNITS) 57
TABLE 11 SYNCHROTRONS MARKET, BY REGION, 2016–2023 (USD MILLION) 57
TABLE 12 SYNCHROTRONS MARKET, BY REGION, 2016–2023 (UNITS) 58
TABLE 13 SYNCHROCYCLOTRONS MARKET, BY REGION, 2016–2023 (USD MILLION) 58
TABLE 14 SYNCHROCYCLOTRONS MARKET, BY REGION, 2016–2023 (UNITS) 59
TABLE 15 PARTICLE THERAPY SERVICES MARKET, BY REGION, 2016–2023 (USD MILLION) 59
TABLE 16 PARTICLE THERAPY MARKET, BY SYSTEM, 2016–2023 (USD MILLION) 61
TABLE 17 PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS, BY REGION,
2016–2023 (USD MILLION) 62
TABLE 18 PARTICLE THERAPY MARKET FOR SINGLE-ROOM SYSTEMS, BY REGION,
2016–2023 (USD MILLION) 63
TABLE 19 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2016–2023 (USD MILLION) 65
TABLE 20 PARTICLE THERAPY MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 70
TABLE 21 PARTICLE THERAPY MARKET FOR TREATMENT APPLICATIONS, BY REGION,
2016–2023 (USD MILLION) 72
TABLE 22 PARTICLE THERAPY MARKET FOR RESEARCH APPLICATIONS, BY REGION,
2016–2023 (USD MILLION) 73
TABLE 23 PARTICLE THERAPY MARKET, BY REGION, 2016–2023 (USD MILLION) 76
TABLE 24 NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY,
2016–2018 (USD MILLION) 78
TABLE 25 NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE,
2016–2023 (USD MILLION) 78
TABLE 26 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 78
TABLE 27 NORTH AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 79
TABLE 28 NORTH AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2023 (UNITS) 79
TABLE 29 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM,
2016–2023 (USD MILLION) 79
TABLE 30 NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 80
TABLE 31 US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 81
TABLE 32 US: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (USD MILLION) 81
TABLE 33 US: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 81
TABLE 34 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 82
TABLE 35 CANADA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2018 (USD MILLION) 82
TABLE 36 CANADA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 83
TABLE 37 EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY, 2016–2018 (USD MILLION) 85
TABLE 38 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 85
TABLE 39 EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 85
TABLE 40 EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2023 (UNITS) 86
TABLE 41 EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 86
TABLE 42 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2016–2023 (USD MILLION) 86
TABLE 43 EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 87
TABLE 44 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 87
TABLE 45 FRANCE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2018 (USD MILLION) 88
TABLE 46 FRANCE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 88
TABLE 47 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 89
TABLE 48 GERMANY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2018 (USD MILLION) 89
TABLE 49 GERMANY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 89
TABLE 50 UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 90
TABLE 51 UK: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (USD MILLION) 91
TABLE 52 UK: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 91
TABLE 53 ROE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 92
TABLE 54 ROE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2018 (USD MILLION) 92
TABLE 55 ROE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 92
TABLE 56 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY,
2016–2018 (USD MILLION) 95
TABLE 57 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 95
TABLE 58 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 95
TABLE 59 ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 96
TABLE 60 ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2023 (UNITS) 96
TABLE 61 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM,
2016–2023 (USD MILLION) 97
TABLE 62 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 97
TABLE 63 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 98
TABLE 64 JAPAN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2018 (USD MILLION) 98
TABLE 65 JAPAN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 99
TABLE 66 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 100
TABLE 67 CHINA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2018 (USD MILLION) 100
TABLE 68 CHINA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 100
TABLE 69 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 101
TABLE 70 INDIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2018 (USD MILLION) 101
TABLE 71 INDIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 102
TABLE 72 ROAPAC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2018 (USD MILLION) 103
TABLE 73 ROAPAC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2018 (USD MILLION) 103
TABLE 74 ROAPAC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2018 (UNITS) 103
TABLE 75 ROW: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 106
TABLE 76 ROW: PARTICLE THERAPY MARKET, BY TYPE, 2016–2023 (USD MILLION) 106
TABLE 77 ROW: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 106
TABLE 78 ROW: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2016–2023 (UNITS) 107
TABLE 79 ROW: PARTICLE THERAPY MARKET, BY SYSTEM, 2016–2023 (USD MILLION) 107
TABLE 80 ROW: PARTICLE THERAPY MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 107


LIST OF FIGURES

FIGURE 1 PARTICLE THERAPY MARKET: RESEARCH METHODOLOGY STEPS 19
FIGURE 2 RESEARCH DESIGN 20
FIGURE 3 BOTTOM-UP APPROACH MARKET SIZE ESTIMATION: PARTICLE THERAPY MARKET 25
FIGURE 4 TOP-DOWN APPROACH MARKET SIZE ESTIMATION: PARTICLE
THERAPY PRODUCT MARKET 26
FIGURE 5 TOP-DOWN APPROACH MARKET SIZE ESTIMATION: PARTICLE
THERAPY SERVICES MARKET 27
FIGURE 6 DATA TRIANGULATION METHODOLOGY 29
FIGURE 7 PARTICLE THERAPY MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION) 31
FIGURE 8 PARTICLE THERAPY PRODUCTS MARKET SHARE, BY TYPE, 2018 VS. 2023 32
FIGURE 9 REGIONAL ANALYSIS: PARTICLE THERAPY MARKET, BY SYSTEM,
2018 (USD MILLION) 33
FIGURE 10 PARTICLE THERAPY MARKET SHARE, BY CANCER TYPE, 2018 VS. 2023 34
FIGURE 11 PARTICLE THERAPY MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION) 34
FIGURE 12 PARTICLE THERAPY MARKET: GEOGRAPHICAL SNAPSHOT 35
FIGURE 13 INCREASING CANCER PREVALENCE IS DRIVING GROWTH OF THE PARTICLE THERAPY MARKET 36
FIGURE 14 SERVICES SEGMENT TO WITNESS HIGH GROWTH IN THE APAC MARKET DURING THE FORECAST PERIOD 37
FIGURE 15 PROTON THERAPY WILL DOMINATE THE MARKET DURING THE FORECAST PERIOD (2018–2023) 37
FIGURE 16 PEDIATRIC CANCER SEGMENT WILL GROW AT THE FASTEST RATE IN THE MARKET DURING THE FORECAST PERIOD 38
FIGURE 17 TREATMENT APPLICATION SEGMENT IS ESTIMATED TO HOLD THE LARGEST SHARE OF THE MARKET GLOBALLY IN 2018 39
FIGURE 18 ASIA PACIFIC TO WITNESS FASTEST GROWTH DURING THE FORECAST PERIOD (2018–2023) 40
FIGURE 20 GROWING INCIDENCE OF CANCER, BY REGION, 2012–2020 (THOUSANDS) 43
FIGURE 21 PROTON THERAPY SEGMENT TO DOMINATE THE PARTICLE THERAPY MARKET DURING THE FORECAST PERIOD 49
FIGURE 22 CYCLOTRONS SEGMENT TO DOMINATE THE PARTICLE THERAPY PRODUCTS MARKET 54
FIGURE 23 MULTI-ROOM SYSTEMS SEGMENT TO DOMINATE THE PARTICLE THERAPY MARKET DURING THE FORECAST PERIOD 61
FIGURE 24 PEDIATRIC CANCER SEGMENT TO WITNESS HIGHEST GROWTH IN THE PARTICLE THERAPY MARKET DURING THE FORECAST PERIOD 65
FIGURE 25 TREATMENT APPLICATIONS TO DOMINATE THE PARTICLE THERAPY MARKET DURING THE FORECAST PERIOD 70
FIGURE 26 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE PARTICLE THERAPY MARKET DURING THE FORECAST PERIOD 75
FIGURE 27 NUMBER OF PARTICLE THERAPY FACILITIES PRESENT (AS OF OCTOBER 2018) & UNDER CONSTRUCTION ACROSS THE GLOBE 76
FIGURE 28 NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT 77
FIGURE 29 EUROPE: PARTICLE THERAPY MARKET SNAPSHOT 84
FIGURE 30 ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT 94
FIGURE 31 ROW: PARTICLE THERAPY MARKET SNAPSHOT 105
FIGURE 32 KEY DEVELOPMENTS BY LEADING MARKET PLAYERS IN THE PARTICLE THERAPY MARKET, 2015–2018 108
FIGURE 33 PARTICLE THERAPY MARKET SHARE, BY KEY PLAYER, 2017 109
FIGURE 34 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT 112
FIGURE 35 ION BEAM APPLICATIONS SA: COMPANY SNAPSHOT 115
FIGURE 36 SUMITOMO HEAVY INDUSTRIES: COMPANY SNAPSHOT 122
FIGURE 37 HITACHI, LTD.: COMPANY SNAPSHOT 124


★調査レポート[粒子線治療の世界市場予測(~2023年)] (コード:MD-6747)販売に関する免責事項を必ずご確認ください。
★調査レポート[粒子線治療の世界市場予測(~2023年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆